What are the recommended preventive therapies for an adult patient with recurrent migraine attacks?

Migraine Prevention: Evidence-Based Pharmacologic Recommendations

Primary Recommendation

For adults with episodic migraine (1-14 headache days per month), initiate monotherapy with either CGRP-targeted therapies (monoclonal antibodies or gepants), β-blockers (metoprolol or propranolol), topiramate, or angiotensin-receptor blockers as first-line preventive treatment. 1

First-Line Treatment Options

The 2025 American College of Physicians guideline establishes several medication classes as appropriate initial monotherapy for episodic migraine prevention 1:

CGRP-Targeted Therapies (Preferred First-Line)

CGRP-targeted therapies should be considered the preferred first-line option based on superior efficacy, tolerability, and migraine-specific mechanism of action. 2

• Monoclonal antibodies: Eptinezumab, erenumab, fremanezumab, or galcanezumab reduce monthly migraine days by 3.2-4.4 days with favorable tolerability profiles 3
• Gepants (oral options): Atogepant or rimegepant provide similar efficacy with the convenience of oral administration 1, 4
• These agents demonstrate vastly superior evidence compared to traditional preventives and do not require failure of other medication classes before initiation 2
• The American Headache Society position statement explicitly endorses CGRP-targeting therapies as first-line without requiring prior treatment failures 2

Traditional First-Line Agents

When CGRP-targeted therapies are not accessible or appropriate:

• β-blockers: Metoprolol or propranolol (timolol also effective but less commonly used) 1, 5
• Antiseizure medications: Topiramate or valproate (note: valproate contraindicated in pregnancy) 1
• Angiotensin-receptor blockers: Candesartan or telmisartan 1
• ACE inhibitors: Lisinopril 1
• Tricyclic antidepressants: Amitriptyline 1, 6

Second-Line Options

If initial treatments are not tolerated or provide inadequate response 1:

• Antidepressants: Venlafaxine (SNRI) or fluoxetine (SSRI), though evidence is more limited 1, 5
• Other agents: Memantine, magnesium citrate 1, 6

Critical Considerations for Treatment Selection

When to Initiate Preventive Therapy

Preventive therapy is indicated when patients experience 5, 6:

• ≥4 migraine attacks per month or ≥8 headache days per month
• Debilitating headaches causing significant disability
• Medication-overuse headaches
• Poor response to or contraindications for acute treatments

Common Pitfall: Underutilization

Only 17% of eligible patients receive preventive therapy despite 40% meeting criteria for treatment 1. This represents a major treatment gap that clinicians must actively address.

Efficacy Expectations

• CGRP-targeted therapies reduce monthly migraine days by approximately 3-4 days on average 3
• Traditional agents show more modest reductions with higher discontinuation rates due to adverse events 3
• Patients require adequate trial duration (typically 8-12 weeks) to assess full therapeutic benefit 6
• Patients with higher baseline migraine frequency or prior treatment failures may require longer treatment periods to reach maximal effect 7

Chronic Migraine (≥15 headache days/month)

For chronic migraine specifically 1, 4:

• OnabotulinumtoxinA is effective for chronic migraine prevention (not recommended for episodic migraine) 1
• CGRP monoclonal antibodies and atogepant have demonstrated efficacy in both episodic and chronic migraine 4

Dosing Considerations

No Dose Adjustments Required For:

• Age, sex, race, or body weight 8
• Mild-to-moderate renal impairment 8
• Concomitant use of common migraine medications (triptans, NSAIDs, acetaminophen) 8

Dose Adjustments Needed:

• Severe hepatic impairment: Reduces atogepant clearance by ~37%; dose adjustment required 8
• Strong CYP3A4 inhibitors (e.g., itraconazole): Decrease clearance by ~66% 8
• Strong CYP3A4 inducers (e.g., rifampin): Increase clearance 1.82-fold 8

Complementary and Non-Pharmacologic Approaches

Evidence supports the following as adjunctive therapies 5, 6:

• Nutraceuticals: Riboflavin (vitamin B2), magnesium citrate, coenzyme Q10 5, 6
• Behavioral interventions: Cognitive-behavioral therapy, relaxation training, biofeedback 5, 6
• Physical therapy and aerobic exercise 1
• Neuromodulation devices show promise but require further standardization 3

Treatment Algorithm

1. Assess eligibility: ≥4 attacks/month or ≥8 headache days/month with significant disability 5
2. First choice: Initiate CGRP-targeted therapy (monoclonal antibody or gepant) given superior efficacy and tolerability 2
3. Alternative first-line: If CGRP therapy unavailable/inappropriate, select from β-blockers, topiramate, ARBs, or amitriptyline based on comorbidities and contraindications 1
4. Trial duration: Allow 8-12 weeks minimum to assess response 6
5. If inadequate response: Switch to alternative first-line agent or consider second-line options 1
6. Add non-pharmacologic therapies: Incorporate behavioral interventions and lifestyle modifications throughout treatment 5, 6

Key Caveat

All ACP recommendations carry conditional strength with low-certainty evidence 1, reflecting the historical limitations of migraine prevention research. However, the evidence base for CGRP-targeted therapies is substantially more robust than for traditional agents, with consistent findings across multiple large randomized trials and extensive real-world experience 2.